deferiprone and Thalassemias studies

Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.

Research Excerpts

Excerpt	Relevance	Reference
" The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited."	9.51	Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022)
" Deferiprone is an oral iron chelator approved for use in the United States as a second line agent for the treatment of transfusional iron overload in patients with thalassemia."	8.95	Deferiprone for the treatment of transfusional iron overload in thalassemia. ( Belmont, A; Kwiatkowski, JL, 2017)
"Deferasirox offers an important treatment option for people with thalassaemia and secondary iron overload."	8.95	Deferasirox for managing iron overload in people with thalassaemia. ( Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK, 2017)
"A meta-analysis was conducted to investigate the efficacy and safety of three main iron chelators, namely, deferoxamine (DFO), deferiprone (DFP) and deferasirox (DFX) for thalassemia major (TM) patients."	8.89	Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. ( Huang, L; Jiang, H; Xia, S; Zhang, W, 2013)
"Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions."	8.83	Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006)
"Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions."	8.83	Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006)
"The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject."	8.81	The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001)
"Iron-overload leads to gut dysbiosis/inflammation and disturbance of metabolites, and deferiprone alleviates those conditions more effectively in WT than in those that are thalassemic."	8.12	Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. ( Buddhasiri, S; Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kittichotirat, W; Kumfu, S; Nawara, W; Sarichai, P; Sriwichaiin, S; Thiennimitr, P; Thonusin, C, 2022)
" Children with thalassemia between 2 and 18 y of age with serum ferritin above 1500 ng/ml were started on oral deferiprone and deferasirox."	8.02	Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. ( Delhikumar, CG; DivakarJose, RR; Ram Kumar, G, 2021)
"Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC)."	7.83	Deferiprone-induced agranulocytosis: 20 years of clinical observations. ( Connelly, J; Galanello, R; Palmblad, J; Rozova, A; Spino, M; Tricta, F; Uetrecht, J, 2016)
"Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event."	7.83	Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016)
"Bony dysplasia, deformation and impaired growth of ulnar epiphyses, metaphyses and physes may be an expression of deferiprone related arthropathy in children with thalassemia major."	7.79	Distal ulnar changes in children with thalassemia and deferiprone related arthropathy. ( Anand, R; Chandra, J; Pemde, H; Seth, A; Sharma, R; Singh, V, 2013)
" The known predisposing factors of infection include prior splenectomy, iron overload and use of iron chelator such as deferoxamine (DFO)."	7.75	Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. ( Chan, GC; Chan, S; Ha, SY; Ho, PL, 2009)
"In this report we firstly describe a case of reactivation of hepatitis B virus (HBV) replication occurred in a patient affected by Thalassemia major which underwent a combined chelation therapy with desferioxamine (DFO) and deferiprone (DFP)."	7.75	Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier. ( Ammirabile, M; Cinque, P; Di Matola, T; Lanza Galeota, A; Prossomariti, L; Ricchi, P, 2009)
"A 10-year-old girl with steroid-resistant Diamond-Blackfan anemia (DBA) developed agranulocytosis 9 weeks after chelation with deferiprone was initiated (45 mg/kg daily, 60% of recommended dose) in addition to her ordinary deferoxamine therapy."	7.74	Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. ( Henter, JI; Karlén, J, 2007)
"For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group comprising 19 patients on a deferiprone (L1) and DFO combination therapy (L1 75-100 mg/kg/day and DFO 30-60 mg/kg, 1-5 days/week), have been studied and compared before and after the introduction of the combination therapy."	7.74	Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2008)
" No unexpected, serious, or severe adverse events were seen in the ES-DFP group."	6.87	Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial. ( Adly, A; Awad, H; Berdoukas, V; Elalfy, MS; Tarif Salam, M; Tricta, F, 2018)
" There was no significant difference in the proportion of patients with adverse events in the two therapy groups although the nature of the adverse events differed according to the chelation regimen."	6.72	A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. ( Fischer, R; Galanello, R; Kattamis, A; Ladis, V; Leoni, G; Lund, U; Piga, A; Tricta, F; Voi, V, 2006)
"The most frequent side effects were joint pain, stiffness or swelling in 6 patients (35."	6.69	Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. ( Chamoun, FM; Khoriaty, AI; Koussa, S; Mourad, FH; Neeman, R; Saad, MA; Taher, A, 1999)
"Deferiprone (L1) is a largely studied oral chelator in clinical setting, however, no definite conclusions concerning efficacy and toxicity still could be drawn."	6.69	Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. ( Amurri, B; De Marco, S; Giua, R; Lazzari, G; Masi, C; Mazza, P; Moscogiuri, R; Palazzo, G; Sebastio, AM; Semeraro, F; Spartera, MA; Suma, V, 1998)
"Some of the thalassemias are non-transfusion-dependent, including many thalassemia intermedia (TI) variants, where iron overload is caused by chronic increase in iron absorption due to ineffective erythropoiesis."	6.53	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016)
"Reversal of arrhythmia to sinus rhythm was noted in all patients."	5.56	Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020)
" The iron chelator deferiprone is frequently used in individuals with thalassemia syndromes, but data in patients with SCD are limited."	5.51	Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. ( Adly, AAM; Alshehri, A; Badr, M; Ebeid, FSE; El-Beshlawy, A; Elalfy, MS; Hamdy, M; Inusa, B; Kanter, J; Kilinc, Y; Kwiatkowski, JL; Lee, D; Tricta, F; Williams, S, 2022)
"An open-label, pilot study was conducted to evaluate deferasirox/deferiprone combination chelation therapy in adult patients with transfusion-dependent thalassemia and severe iron overload."	5.30	Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. ( Fogel, MA; Hammond, J; Hammond, K; Kokroko, J; Kwiatkowski, JL; Thompson, AA, 2019)
" Pharmacokinetic values were calculated."	5.29	Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients. ( Bentur, Y; Fernandes, D; Klein, J; Koren, G; Matsui, D; Olivieri, N; Stobie, S; Tyberg, J, 1993)
" Transfusional iron overload in patients with thalassaemia could be reduced to normal body iron range levels using effective deferiprone/deferoxamine combinations."	5.14	Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. ( Kleanthous, M; Kolnagou, A; Kontoghiorghes, GJ, 2010)
" The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and deferoxamine (DFO) in reducing transfusional iron overload compared to either drug alone and to assess the safety and tolerability of DFP."	5.13	Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. ( El-Beshlawy, A; Eltagui, M; Hamdy, M; Hoffbrand, AV; Manz, C; Mostafa, A; Naja, M; Shaker, O; Sharaf, I; Sobh, H; Taher, A; Tarabishi, C; Youssry, I, 2008)
"Agranulocytosis developed in a 63-year-old patient with myelodysplasia 6 weeks after commencing treatment with the oral iron chelator deferiprone (L1, 1,2-dimethyl-3-hydroxypyrid-4-one, CP20) at a daily dose of 79 mg/kg."	5.07	Deferiprone-associated myelotoxicity. ( al-Refaie, FN; Hoffbrand, AV; Wonke, B, 1994)
"To compare the efficacy and safety of desferrioxamine (DFO), deferiprone (DFP), deferasirox (DFX) and silymarin in patients with either thalassemia or sickle cell disorder through network meta-analysis."	4.98	Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. ( Sivaramakrishnan, G; Sridharan, K, 2018)
"Deferasirox offers an important treatment option for people with thalassaemia and secondary iron overload."	4.95	Deferasirox for managing iron overload in people with thalassaemia. ( Allert, R; Bassler, D; Bollig, C; Meerpohl, JJ; Motschall, E; Niemeyer, CM; Rücker, G; Schell, LK, 2017)
" Deferiprone is an oral iron chelator approved for use in the United States as a second line agent for the treatment of transfusional iron overload in patients with thalassemia."	4.95	Deferiprone for the treatment of transfusional iron overload in thalassemia. ( Belmont, A; Kwiatkowski, JL, 2017)
"A meta-analysis was conducted to investigate the efficacy and safety of three main iron chelators, namely, deferoxamine (DFO), deferiprone (DFP) and deferasirox (DFX) for thalassemia major (TM) patients."	4.89	Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. ( Huang, L; Jiang, H; Xia, S; Zhang, W, 2013)
"In the absence of data from randomised controlled trials, there is no evidence to suggest the need for a change in current treatment recommendations; namely that deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate."	4.89	Oral deferiprone for iron chelation in people with thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013)
"Desferrioxamine is the recommended first-line therapy for iron overload in people with thalassaemia major and deferiprone or deferasirox are indicated for treating iron overload when desferrioxamine is contraindicated or inadequate."	4.89	Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. ( Brunskill, SJ; Chowdhury, O; Doree, C; Fisher, SA; Gooding, S; Roberts, DJ, 2013)
"We found no reason to change current treatment recommendations, namely deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate."	4.84	Oral deferiprone for iron chelation in people with thalassaemia. ( Brunskill, SJ; Doree, C; Howard, J; Hyde, CJ; Roberts, DJ; Williams, S, 2007)
"The iron chelators deferoxamine (DFO) and deferiprone (L1) have demonstrated their ability to normalize cardiac function in patients with iron overload-induced cardiac disease."	4.84	Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. ( Peng, CT; Tsai, CH; Wu, KH, 2008)
"Iron mobilization from transferrin is one of the most important screening methods for the selection of chelators intended for clinical use in the treatment of iron overload in thalassemia and other conditions."	4.83	Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. ( Kontoghiorghes, GJ, 2006)
"Deferiprone (L1), and appropriate combinations with deferoxamine (DFO), can be used effectively for the treatment of thalassemia and other transfusional iron loading conditions."	4.83	Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. ( Kontoghiorghes, GJ, 2006)
" As LPI is detected primarily in patients with transfusional iron overload and other forms of hemosiderosis, we review here regimens of iron chelation with deferrioxamine and deferiprone (separately or combined) in terms of their efficacy in minimizing daily exposure to LPI in thalassemia major and thalassemia intermedia patients."	4.82	LPI-labile plasma iron in iron overload. ( Breuer, W; Cabantchik, ZI; Cianciulli, P; Zanninelli, G, 2005)
"In patients with thalassemia, the assessment of liver iron concentration (LIC) can be used to initiate chelation treatment with desferrioxamine (DFO), deferiprone (DFP), or novel chelators (deferasirox); to adjust chelation dose according to the actual blood transfusion rate; and to monitor chelation efficacy."	4.82	Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. ( Fischer, R; Harmatz, P; Nielsen, P; Piga, A, 2005)
"Therapy with either deferiprone (DFP) or deferoxamine (DFO) is inadequate in achieving negative iron balance in many patients with thalassemia."	4.82	Combined therapy with deferoxamine and deferiprone. ( Kattamis, A, 2005)
"The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject."	4.81	The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001)
"Data from several trials have provided direct and supportive evidence for the efficacy of deferiprone in the treatment of iron overload in thalassemia major."	4.79	Long-term therapy with deferiprone. ( Olivieri, NF, 1996)
"Deferiprone is the most widely studied oral iron chelator and, at present, the only one shown to be effective in achieving negative iron balance in long-term clinical trials for chronic iron overload."	4.79	Oral iron chelation with deferiprone. ( Diav-Citrin, O; Koren, G, 1997)
"Iron-overload leads to gut dysbiosis/inflammation and disturbance of metabolites, and deferiprone alleviates those conditions more effectively in WT than in those that are thalassemic."	4.12	Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. ( Buddhasiri, S; Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kittichotirat, W; Kumfu, S; Nawara, W; Sarichai, P; Sriwichaiin, S; Thiennimitr, P; Thonusin, C, 2022)
" Children with thalassemia between 2 and 18 y of age with serum ferritin above 1500 ng/ml were started on oral deferiprone and deferasirox."	4.02	Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. ( Delhikumar, CG; DivakarJose, RR; Ram Kumar, G, 2021)
" Here we report the case of a 9-year-old child with thalassaemia who developed frequent premature ventricular contractions after three doses of filgrastim were given for deferiprone-induced agranulocytosis."	3.88	Premature ventricular contractions as a side effect of filgrastim in a child with B-thalassaemia. ( Joshi, N; Nazir, HF; Wali, YA, 2018)
"To compare the efficacy and safety of oral iron chelators (Deferiprone and Deferasirox) when used singly and in combination in multi-transfused children with thalassemia."	3.83	Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. ( Gomber, S; Jain, P; Narang, M; Sharma, S, 2016)
"Use of the iron chelator deferiprone for treatment of iron overload in thalassemia patients is associated with concerns over agranulocytosis, which requires weekly absolute neutrophil counts (ANC)."	3.83	Deferiprone-induced agranulocytosis: 20 years of clinical observations. ( Connelly, J; Galanello, R; Palmblad, J; Rozova, A; Spino, M; Tricta, F; Uetrecht, J, 2016)
"Weekly monitoring of absolute neutrophil count (ANC) under deferiprone therapy in thalassemia patients is recommended to avoid agranulocytosis adverse event."	3.83	Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. ( Belen, BF; Özsevik, SN; Polat, M; Soylu, E, 2016)
" The complete treatment of transfusional iron overload in thalassaemia using the deferiprone (L1) and deferoxamine combination is a paradigm to be followed in the treatment of many other metal toxicity conditions."	3.79	The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies. ( Kontoghiorghes, GJ, 2013)
"Bony dysplasia, deformation and impaired growth of ulnar epiphyses, metaphyses and physes may be an expression of deferiprone related arthropathy in children with thalassemia major."	3.79	Distal ulnar changes in children with thalassemia and deferiprone related arthropathy. ( Anand, R; Chandra, J; Pemde, H; Seth, A; Sharma, R; Singh, V, 2013)
" The generic drugs deferiprone, deferoxamine and their combination offer a safer, less expensive and complete treatment of iron overload in thalassaemia and other iron loading conditions."	3.79	A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? ( Kontoghiorghes, GJ, 2013)
"Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion-dependent thalassemia."	3.76	Deferiprone. ( Longo, F; Massano, D; Piga, A; Roggero, S; Salussolia, I; Serra, M, 2010)
"In iron overload conditions, plasma contains non-transferrin bound iron species, collectively referred to as plasma NTBI."	3.76	Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. ( Eccleston, J; Evans, P; Hider, RC; Kayyali, R; Porter, JB, 2010)
" The known predisposing factors of infection include prior splenectomy, iron overload and use of iron chelator such as deferoxamine (DFO)."	3.75	Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. ( Chan, GC; Chan, S; Ha, SY; Ho, PL, 2009)
" The introduction of effective chelation therapy protocols using primarily deferiprone (L1) in combination with deferoxamine (DFO) resulted in the reduction of iron overload induced cardiac failures, which is the main cause of death in thalassemia major."	3.75	Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. ( Kolnagou, A; Kontoghiorghes, GJ, 2009)
"In this report we firstly describe a case of reactivation of hepatitis B virus (HBV) replication occurred in a patient affected by Thalassemia major which underwent a combined chelation therapy with desferioxamine (DFO) and deferiprone (DFP)."	3.75	Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier. ( Ammirabile, M; Cinque, P; Di Matola, T; Lanza Galeota, A; Prossomariti, L; Ricchi, P, 2009)
"Non-transferrin-bound iron (NTBI) is detectable in plasma of beta-thalassemia patients with transfusional iron overload."	3.74	Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma. ( Fucharoen, S; Phisalaphong, C; Porter, JB; Srichairatanakool, S; Thephinlap, C, 2007)
"For the past 2-6 years, two groups of thalassemia patients, one of 16 patients on deferoxamine (DFO) monotherapy (35-80 mg/kg, 2-5 days/week) and the other group comprising 19 patients on a deferiprone (L1) and DFO combination therapy (L1 75-100 mg/kg/day and DFO 30-60 mg/kg, 1-5 days/week), have been studied and compared before and after the introduction of the combination therapy."	3.74	Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2008)
"A 10-year-old girl with steroid-resistant Diamond-Blackfan anemia (DBA) developed agranulocytosis 9 weeks after chelation with deferiprone was initiated (45 mg/kg daily, 60% of recommended dose) in addition to her ordinary deferoxamine therapy."	3.74	Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. ( Henter, JI; Karlén, J, 2007)
"The incidence of cardiomyopathy was monitored in a 6-year follow-up study involving 56 transfused thalassemia patients treated with deferoxamine (DFO), deferiprone (L1) or their combination."	3.73	Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. ( Economides, C; Eracleous, E; Kolnagou, A; Kontoghiorghes, GJ, 2006)
" No unexpected, serious, or severe adverse events were seen in the ES-DFP group."	2.87	Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial. ( Adly, A; Awad, H; Berdoukas, V; Elalfy, MS; Tarif Salam, M; Tricta, F, 2018)
" There was no significant difference in the proportion of patients with adverse events in the two therapy groups although the nature of the adverse events differed according to the chelation regimen."	2.72	A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. ( Fischer, R; Galanello, R; Kattamis, A; Ladis, V; Leoni, G; Lund, U; Piga, A; Tricta, F; Voi, V, 2006)
"Deferiprone is an effective iron chelator, but arthropathy and neutropenia are very frequent side effects and need strict monitoring during therapy."	2.71	Deferiprone, efficacy and safety. ( Choudhry, VP; Malaviya, AN; Pati, HP; Saxena, A, 2004)
"Thrombocytopenia was observed in 20 patients (45."	2.71	Safety of oral iron chelator deferiprone in young thalassaemics. ( Chandra, J; Naithani, R; Sharma, S, 2005)
"Deferiprone (L1) is a largely studied oral chelator in clinical setting, however, no definite conclusions concerning efficacy and toxicity still could be drawn."	2.69	Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. ( Amurri, B; De Marco, S; Giua, R; Lazzari, G; Masi, C; Mazza, P; Moscogiuri, R; Palazzo, G; Sebastio, AM; Semeraro, F; Spartera, MA; Suma, V, 1998)
"The most frequent side effects were joint pain, stiffness or swelling in 6 patients (35."	2.69	Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. ( Chamoun, FM; Khoriaty, AI; Koussa, S; Mourad, FH; Neeman, R; Saad, MA; Taher, A, 1999)
" One month later each patient received the other of the 2 dosing regimens for 72 hours immediately prior to transfusion."	2.68	The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. ( Fassos, FF; Fernandes, D; Klein, J; Koren, G; Matsui, D; Olivieri, NF, 1996)
" During the course of the trial, several possible adverse effects have been encountered."	2.67	Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. ( al-Refaie, FN; Hoffbrand, AV; Kontoghiorghes, GJ; Nortey, P; Wickens, DG; Wonke, B, 1992)
"Some of the thalassemias are non-transfusion-dependent, including many thalassemia intermedia (TI) variants, where iron overload is caused by chronic increase in iron absorption due to ineffective erythropoiesis."	2.53	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. ( Kontoghiorghe, CN; Kontoghiorghes, GJ, 2016)
"Iron overload has many different causes, both genetic and environmental."	2.48	Iron mobilization using chelation and phlebotomy. ( Aaseth, J; Andersen, O; Flaten, TP; Kontoghiorghes, GJ, 2012)
"Monitoring of iron overload has advanced with the increasing use of MRI techniques to estimate iron balance (changes in liver iron concentration) and extrahepatic iron distribution (myocardial T2*)."	2.46	Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. ( Porter, JB; Shah, FT, 2010)
"Iron overload is a major cause of morbidity and mortality in transfusion-dependent anemias."	2.46	An update on disordered iron metabolism and iron overload. ( Ward, R, 2010)
"Deferiprone is a three-times-daily oral iron chelator, but has limited availability in the United States."	2.44	Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. ( Baladi, JF; Coates, TD; Delea, TE; Edelsberg, J; Phatak, PD; Sofrygin, O; Thomas, SK, 2007)
"If untreated, iron overload is responsible for heart, liver and endocrine diseases."	2.42	Pharmacotherapy of iron overload in thalassaemic patients. ( Ceci, A; De Mattia, D; De Sanctis, V; Felisi, M, 2003)
"Reversal of arrhythmia to sinus rhythm was noted in all patients."	1.56	Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. ( Chao, YH; Chuang, TY; Li, JP; Weng, TF; Wu, KH, 2020)
"Cardiac iron overload was induced to a greater extent than in a previous study by feeding the mice with an iron-enriched diet for 4 months."	1.43	Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. ( Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S, 2016)
"There is a lack of knowledge regarding the incidence of serious adverse drug reactions (ADR) to the oral iron chelator deferiprone in Chinese children with transfusion-dependent thalassaemia."	1.43	Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia. ( Botzenhardt, S; Ceci, A; Chan, GC; Felisi, M; Neubert, A; Rascher, W; Sing, CW; Wong, IC; Wong, LY, 2016)
"Thalassemia is a chronic hereditary disease in which patients with severe disease present with anemia during their first year of life."	1.37	Health-related quality of life in Thai thalassemic children treated with iron chelation. ( Pankaew, T; Torcharus, K, 2011)
"Dental caries were significantly higher in thalassemics."	1.33	Physical growth patterns and dental caries in thalassemia. ( Dewan, P; Gomber, S, 2006)
" The results show that L1 is less toxic than DF to normal bone marrow myeloid progenitors (ID50:130 mumol/l versus 7."	1.29	Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. ( al-Refaie, FN; Cunningham, JM; Hoffbrand, AV; Hunter, AE; Sheppard, LN, 1994)
" Pharmacokinetic values were calculated."	1.29	Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients. ( Bentur, Y; Fernandes, D; Klein, J; Koren, G; Matsui, D; Olivieri, N; Stobie, S; Tyberg, J, 1993)
" Food prolongs the rate of absorption of L1, but it does not affect significantly the extent of absorption measured by the area under the plasma concentration-time curve."	1.28	Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. ( Chung, D; Grunau, V; Hermann, C; Klein, J; Koren, G; Matsui, D; McClelland, R; Olivieri, N; St-Louis, P, 1991)

Research

Studies (167)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Change From Baseline in Cardiac Iron

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (2.40)	18.7374
1990's	43 (25.75)	18.2507
2000's	62 (37.13)	29.6817
2010's	49 (29.34)	24.3611
2020's	9 (5.39)	2.80

Authors	Studies
Kwiatkowski, JL	4
Hamdy, M	2
El-Beshlawy, A	2
Ebeid, FSE	1
Badr, M	1
Alshehri, A	1
Kanter, J	1
Inusa, B	1
Adly, AAM	1
Williams, S	2
Kilinc, Y	1
Lee, D	1
Tricta, F	4
Elalfy, MS	2
Sriwichaiin, S	1
Thiennimitr, P	1
Thonusin, C	1
Sarichai, P	1
Buddhasiri, S	1
Kumfu, S	4
Nawara, W	1
Kittichotirat, W	1
Fucharoen, S	7
Chattipakorn, N	5
Chattipakorn, SC	5
Kolnagou, A	13
Kleanthous, M	3
Kontoghiorghes, GJ	32
Sumneang, N	1
Khamseekaew, J	3
Siri-Angkul, N	1
Sripetchwandee, J	1
Svasti, S	1
Srichairatanakool, S	3
Schafer, A	1
DivakarJose, RR	1
Delhikumar, CG	1
Ram Kumar, G	1
Chuang, TY	1
Li, JP	1
Weng, TF	1
Wu, KH	3
Chao, YH	1
Peyam, S	1
Bansal, D	1
Zardkhoni, SZ	1
Moghaddam, AG	1
Rad, F	1
Ghatee, MA	1
Omidifar, N	1
Ghaedi, M	1
Etemadfar, P	1
Hadjidemetriou, M	1
Belmont, A	1
Bollig, C	1
Schell, LK	1
Rücker, G	1
Allert, R	1
Motschall, E	1
Niemeyer, CM	1
Bassler, D	1
Meerpohl, JJ	1
Nazir, HF	1
Joshi, N	1
Wali, YA	1
Adly, A	1
Awad, H	1
Tarif Salam, M	1
Berdoukas, V	4
Karakas, Z	1
Yilmaz, Y	1
Bayramoglu, Z	1
Karaman, S	1
Aydogdu, S	1
Karagenc, AO	1
Tugcu, D	1
Dursun, M	1
Sridharan, K	1
Sivaramakrishnan, G	1
Sriwantana, T	1
Vivithanaporn, P	1
Paiboonsukwong, K	1
Rattanawonsakul, K	1
Srihirun, S	1
Sibmooh, N	1
Wahidiyat, PA	1
Yosia, M	1
Sari, TT	1
Pinto, VM	1
Balocco, M	1
Quintino, S	1
Bacigalupo, L	1
Gianesin, B	1
Rizzi, M	1
Malagò, R	1
De Franceschi, L	1
Forni, GL	1
Hammond, J	1
Thompson, AA	1
Fogel, MA	1
Hammond, K	1
Kokroko, J	1
Hider, RC	2
Hoffbrand, AV	14
Vitrano, A	2
Ruffo, GB	1
Pepe, A	3
D'Ascola, DG	2
Caruso, V	2
Filosa, A	3
Masera, N	1
Pitrolo, L	1
Rigano, P	2
Cuccia, L	2
Giangreco, A	1
Di Maggio, R	1
Maggio, A	4
Olivieri, NF	9
Brittenham, GM	1
Sharma, R	1
Anand, R	1
Chandra, J	2
Seth, A	1
Pemde, H	1
Singh, V	1
Fisher, SA	2
Brunskill, SJ	3
Doree, C	3
Gooding, S	2
Chowdhury, O	2
Roberts, DJ	4
Xia, S	1
Zhang, W	1
Huang, L	1
Jiang, H	1
Tanphaichitr, A	1
Kusuwan, T	1
Limviriyakul, S	1
Atipas, S	1
Pooliam, J	1
Sangpraypan, T	1
Tanphaichitr, VS	1
Viprakasit, V	1
Choengchan, N	1
Mantim, T	1
Inpota, P	1
Nacapricha, D	1
Wilairat, P	1
Jittangprasert, P	1
Waiyawat, W	1
Sirankpracha, P	1
Morales, NP	1
Botzenhardt, S	1
Sing, CW	1
Wong, IC	1
Chan, GC	2
Wong, LY	1
Felisi, M	3
Rascher, W	1
Ceci, A	3
Neubert, A	1
Conte, R	1
Ruggieri, L	1
Gambino, A	1
Bartoloni, F	1
Baiardi, P	1
Bonifazi, D	1
Bonifazi, F	1
Giannuzzi, V	1
Padula, R	1
Putti, MC	1
Del Vecchio, GC	1
Iacono, A	1
Mangiarini, L	1
Kontoghiorghe, CN	1
Belen, BF	1
Polat, M	1
Özsevik, SN	1
Soylu, E	1
Gomber, S	3
Jain, P	1
Sharma, S	2
Narang, M	1
Economou, M	1
Teli, A	1
Gourtsa, V	1
Vargiami, E	1
Zafeiriou, D	1
Uetrecht, J	1
Galanello, R	2
Connelly, J	1
Rozova, A	1
Spino, M	1
Palmblad, J	1
Wongjaikam, S	1
Kerdphoo, S	1
Jaiwongkam, T	1
Ricchi, P	1
Cinque, P	1
Lanza Galeota, A	1
Di Matola, T	1
Ammirabile, M	1
Prossomariti, L	2
Capra, M	1
Gagliardotto, F	1
Romeo, MA	1
Magnano, C	1
Argento, C	1
Gerardi, C	1
Campisi, S	1
Violi, P	1
Malizia, R	1
Cianciulli, P	2
Rizzo, M	1
Quota, A	1
Fidone, C	1
D'Amico, G	2
Morabito, A	2
Gluud, C	1
Yazman, D	1
Economides, C	5
Eracleous, E	4
Chan, S	1
Ho, PL	1
Ha, SY	1
Efstathiou, A	1
Michaelides, Y	2
Carson, S	1
Nord, A	1
Dongelyan, A	1
Gavin, S	1
Hofstra, TC	1
Wood, JC	2
Coates, T	2
Evans, P	1
Kayyali, R	1
Eccleston, J	1
Porter, JB	3
Hershko, C	4
Piga, A	5
Roggero, S	2
Salussolia, I	1
Massano, D	1
Serra, M	1
Longo, F	2
Ward, R	1
Shah, FT	1
Farmaki, K	1
Jamuar, SS	1
Lai, AH	1
Tan, AM	1
Chan, MY	1
Tan, ES	1
Ng, IS	1
Shuchman, M	2
Traynor, K	1
Verma, IC	1
Saxena, R	2
Kohli, S	1
Torcharus, K	1
Pankaew, T	1
Flaten, TP	1
Aaseth, J	1
Andersen, O	1
Somerville, MA	1
Datta, S	1
Constantinou, G	1
Melides, S	1
Modell, B	2
di Norcia, V	1
Lucas, GN	1
Perera, BJ	1
Fonseka, EA	1
De Silva, DD	1
Fernandopulle, M	1
Karunatilaka, DH	1
Weerasinghe, I	1
Nathan, DG	2
De Sanctis, V	2
De Mattia, D	1
Di Stefano, M	1
Chiabotto, P	1
Roggia, C	1
Garofalo, F	1
Lala, R	1
Isaia, GC	1
Dyer, C	1
Downie, J	1
Baird, P	1
Thompson, J	1
Madan, N	1
Choudhry, VP	1
Pati, HP	1
Saxena, A	1
Malaviya, AN	1
Bulterman, M	1
Fessas, C	1
Papatryphonas, A	1
Taher, A	4
Aoun, E	1
Sharara, AI	1
Mourad, F	1
Gharzuddine, W	1
Koussa, S	3
Inati, A	1
Dhillon, AP	1
Naithani, R	1
Cabantchik, ZI	2
Breuer, W	1
Zanninelli, G	1
Rees, D	1
Howard, J	2
Hyde, C	1
Alderson, P	1
Brunskill, S	1
Link, G	2
Konijn, AM	2
Kattamis, A	2
Vinciguerra, T	1
Sacchetti, L	1
Gallo, V	1
Fischer, R	2
Harmatz, P	1
Nielsen, P	1
Pennell, DJ	1
Chen, AC	1
Peng, CT	2
Wu, SF	1
Chiang, IP	1
Tsai, CH	2
Mudiyanse, RM	1
Telfer, P	1
Coen, PG	1
Christou, S	1
Hadjigavriel, M	1
Kolnakou, A	1
Pangalou, E	1
Pavlides, N	1
Psiloines, M	1
Simamonian, K	1
Skordos, G	1
Sitarou, M	1
Angastiniotis, M	1
Leoni, G	1
Ladis, V	1
Voi, V	1
Lund, U	1
Dewan, P	1
Henter, JI	1
Karlén, J	1
Hyde, CJ	1
Delea, TE	1
Edelsberg, J	1
Sofrygin, O	1
Thomas, SK	1
Baladi, JF	1
Phatak, PD	1
Coates, TD	1
Thephinlap, C	1
Phisalaphong, C	1
Kidson-Gerber, GL	1
Francis, S	1
Lindeman, R	1
Kontos, C	1
Kyriacou, K	1
Manz, C	1
Naja, M	1
Eltagui, M	1
Tarabishi, C	1
Youssry, I	1
Sobh, H	1
Sharaf, I	1
Mostafa, A	1
Shaker, O	1
Mehta, J	3
Singhal, S	3
Mehta, BC	3
Adhikari, D	1
al-Refaie, FN	5
Wonke, B	6
Vreugdenhil, G	1
Smeets, M	1
Broekhuysen, AM	1
Bichile, SK	1
Mehta, PJ	1
Parekh, SJ	1
Chablani, A	2
Reporter, R	1
Wickens, DG	2
Aydinok, Y	1
Fielding, A	1
Cunningham, JM	1
Hunter, AE	1
Sheppard, LN	2
Stobie, S	1
Tyberg, J	1
Matsui, D	5
Fernandes, D	2
Klein, J	5
Olivieri, N	3
Bentur, Y	2
Koren, G	11
Kowdley, KV	1
Tavill, AS	1
Fassos, FF	1
Diav-Citrin, O	1
Dogherty, P	1
Einarson, T	1
Sher, G	1
Browne, PV	1
Shalev, O	2
Kuypers, FA	1
Brugnara, C	1
Solovey, A	1
Mohandas, N	1
Schrier, SL	1
Hebbel, RP	2
Mazza, P	1
Amurri, B	1
Lazzari, G	1
Masi, C	1
Palazzo, G	1
Spartera, MA	1
Giua, R	1
Sebastio, AM	1
Suma, V	1
De Marco, S	1
Semeraro, F	1
Moscogiuri, R	1
Wright, C	1
Buchwald, M	1
O'Brodovich, H	1
Birmingham, K	1
Chamoun, FM	1
Saad, MA	1
Khoriaty, AI	1
Neeman, R	1
Mourad, FH	2
Weatherall, DJ	2
Hileti, D	1
Nortey, P	4
Hoffbrand, VA	1
Rombos, Y	1
Tzanetea, R	1
Konstantopoulos, K	1
Simitzis, S	1
Zervas, C	1
Kyriaki, P	1
Kavouklis, M	1
Aessopos, A	1
Sakellaropoulos, N	1
Karagiorga, M	1
Kalotychou, V	1
Loukopoulos, D	1
Agarwal, MB	4
Grady, RW	1
Marx, JJ	2
Pippard, MJ	1
Tondury, P	2
Richardson, DR	1
Bonetta, L	1
Rouan, MC	1
Marfil, F	1
Mangoni, P	1
Séchaud, R	1
Humbert, H	1
Maurer, G	1
Zahed, L	1
Alameddine, R	1
Aoun, S	1
Liu, PP	1
Blendis, L	1
Cameron, R	1
McClelland, RA	4
Templeton, DM	4
Revankar, R	1
Walvalkar, A	1
Hermann, C	4
Chandy, M	1
Gupte, SS	2
Vasandani, D	2
Viswanathan, C	2
Puniyani, RR	2
Ramanathan, J	2
Massil, DE	2
Shah, S	2
Rajyadhyaksha, GC	1
Bhave, AA	1
Grunau, V	1
McClelland, R	1
Chung, D	4
St-Louis, P	1
St Louis, P	2
Freedman, MH	3
Damani, LA	1
Epemoulu, O	1
Bartlett, AN	3
Goddard, JG	3
Sheppard, L	2
Barr, J	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias[NCT02041299]	Phase 4	230 participants (Actual)	Interventional	2014-04-17	Terminated (stopped due to Difficulties with additional recruitment as pool of potential patients was exhausted, and sufficient information for determination of study outcome measure was already obtained)
Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox[NCT03358498]		75 participants (Anticipated)	Observational	2017-12-01	Not yet recruiting
A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study[NCT02173951]	Phase 2/Phase 3	64 participants (Anticipated)	Interventional	2014-07-31	Not yet recruiting
Phase IV Study of the Use of Sequential DFP-DFO Versus DFP in Thalassemia Major Patients[NCT00733811]	Phase 4	213 participants (Actual)	Interventional	2000-09-30	Completed
Prospective Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut University Children Hospital (AUCH)[NCT05303506]		50 participants (Anticipated)	Observational	2022-07-02	Not yet recruiting
Randomized Open-label Phase III Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients[NCT00350662]	Phase 3	95 participants (Actual)	Interventional	2002-01-31	Completed
Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients[NCT00349453]	Phase 2	24 participants (Actual)	Interventional	2005-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Cardiac iron is measured by MRI in milliseconds (ms). A score of less than 20 ms is indicative of cardiac iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52

Change From Baseline in Liver Iron Concentration (LIC)

Intervention	milliseconds (Least Squares Mean)
Deferiprone	-0.022068
Deferoxamine	-0.021773

LIC was measured by MRI. A score >7 mg/g dw is indicative of iron overload. (NCT02041299)
Timeframe: Change from baseline to Week 52

Change From Baseline in Serum Ferritin

Intervention	mg of iron per gram of liver dry weight (Least Squares Mean)
Deferiprone	-4.13
Deferoxamine	-4.38

Serum ferritin provides a measure of iron level in the blood. Normal levels of serum ferritin are under 300 µg/L for females and 400 µg/L for males. (NCT02041299)
Timeframe: Change from baseline to Week 52

Change in Patient-reported Quality of Life, as Measured by the Short Form Health Survey (SF-36) or the Child Health Questionnaire (CHQ-PF50).

Intervention	micrograms per liter (Least Squares Mean)
Deferiprone	-385.83
Deferoxamine	-760.89

Adult patients completed the SF-36 questionnaire and minors completed the CHQ-PF50. These questionnaires yield a profile of functional health and well-being, based on 8 scales of physical and mental health measures: Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and Mental Health (MH), and summary scores are produced for physical well-being and mental well-being. The summaries are scored from 0-100, with higher scores reflecting better outcomes. (NCT02041299)
Timeframe: Change from baseline to Week 52

Intervention	score on a scale (Mean)
	SF-36 Physical Summary	SF-36 Mental Summary	CHQ-PF50 Physical Summary	CHQ-PF50 Psychosocial Summary
Deferiprone	43.1	44.7	29.3	42.5
Deferoxamine	43.0	40.9	30.5	41.3

Article	Year
Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease. Frontiers in bioscience (Elite edition), 2022, 07-12, Volume: 14, Issue:3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; R	2022
Clinical Challenges with Iron Chelation in Beta Thalassemia. Hematology/oncology clinics of North America, 2023, Volume: 37, Issue:2 Topics: beta-Thalassemia; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overload; Pyr	2023
Deferiprone for the treatment of transfusional iron overload in thalassemia. Expert review of hematology, 2017, Volume: 10, Issue:6 Topics: Deferiprone; Erythrocyte Transfusion; Humans; Iron; Iron Overload; Myocardium; Neutropenia; Pyridone	2017
Deferasirox for managing iron overload in people with thalassaemia. The Cochrane database of systematic reviews, 2017, 08-15, Volume: 8 Topics: Administration, Oral; Benzoates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T	2017
Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:6 Topics: Anemia, Sickle Cell; Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; H	2018
Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report. Acta medica Indonesiana, 2018, Volume: 50, Issue:2 Topics: Benzoates; Child; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Heart; Humans;	2018
The Role of Deferiprone in Iron Chelation. The New England journal of medicine, 2018, 11-29, Volume: 379, Issue:22 Topics: Anemia, Sickle Cell; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combination; Erythr	2018
Management of the thalassemias. Cold Spring Harbor perspectives in medicine, 2013, Jun-01, Volume: 3, Issue:6 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron	2013
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane database of systematic reviews, 2013, Aug-21, Issue:8 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents;	2013
Oral deferiprone for iron chelation in people with thalassaemia. The Cochrane database of systematic reviews, 2013, Aug-21, Issue:8 Topics: Administration, Oral; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; I	2013
Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PloS one, 2013, Volume: 8, Issue:12 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelating Agents; L	2013
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug design, development and therapy, 2016, Volume: 10 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents;	2016
An update on disordered iron metabolism and iron overload. Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:5 Topics: Animals; Blood Transfusion; Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron; Iron	2010
Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron	2010
Past, present & future scenario of thalassaemic care & control in India. The Indian journal of medical research, 2011, Volume: 134 Topics: Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Female; Genetic Carrier Screening; Humans; I	2011
Deferiprone (Ferriprox) for iron overload. The Medical letter on drugs and therapeutics, 2012, Feb-20, Volume: 54, Issue:1384 Topics: Animals; Clinical Trials as Topic; Deferiprone; Humans; Iron Overload; Pyridones; Thalassemia; Trans	2012
Iron mobilization using chelation and phlebotomy. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS), 2012, Volume: 26, Issue:2-3 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Iron Overloa	2012
Clinical research: a tale of two studies. Transactions of the American Clinical and Climatological Association, 2003, Volume: 114 Topics: Benzoates; Biomedical Research; Cooperative Behavior; Deferasirox; Deferiprone; Drug Design; Drug In	2003
Pharmacotherapy of iron overload in thalassaemic patients. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:10 Topics: Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; I	2003
LPI-labile plasma iron in iron overload. Best practice & research. Clinical haematology, 2005, Volume: 18, Issue:2 Topics: beta-Thalassemia; Deferiprone; Humans; Iron; Iron Chelating Agents; Iron Overload; Oxidation-Reducti	2005
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. The Cochrane database of systematic reviews, 2005, Oct-19, Issue:4 Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone	2005
Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Current medicinal chemistry, 2005, Volume: 12, Issue:23 Topics: Benzoates; Carboxylic Acids; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemo	2005
Objectives and mechanism of iron chelation therapy. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Animals; Benzoates; Cardiomyopathies; Cells, Cultured; Chelation Therapy; Clinical Trials as Topic;	2005
Combined therapy with deferoxamine and deferiprone. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Agranulocytosis; Biological Transport; Cardiomyopathies; Chelation Therapy; Clinical Trials as Topic	2005
Deferiprone: New insight. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St	2005
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Algorithms; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine;	2005
T2* magnetic resonance and myocardial iron in thalassemia. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Adult; Calibration; Cardiomyopathies; Chelation Therapy; Child; Cohort Studies; Combined Modality Th	2005
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Anemia; Chelation Therapy; Chronic Disease; Combined Modality Therapy; Deferiprone; Humans; Iron; Ir	2006
Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Benzoates; Carboxylic Acids; Chelation Therapy; Clinical Trials as Topic; Deferasirox; Deferiprone;	2006
Oral deferiprone for iron chelation in people with thalassaemia. The Cochrane database of systematic reviews, 2007, Jul-18, Issue:3 Topics: Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyridone	2007
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion, 2007, Volume: 47, Issue:10 Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cost of Illness; Deferiprone; Deferoxamine; Humans	2007
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Approval; Drug Therapy, C	2008
Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron; Iron Chelat	2008
Long-term therapy with deferiprone. Acta haematologica, 1996, Volume: 95, Issue:1 Topics: Animals; Clinical Trials as Topic; Deferiprone; Drug Approval; Hemosiderosis; Humans; Iron; Iron Che	1996
Oral iron chelation with deferiprone. Pediatric clinics of North America, 1997, Volume: 44, Issue:1 Topics: Acute Disease; Administration, Oral; Anemia; Chelation Therapy; Child; Deferiprone; Humans; Iron Ove	1997
Iron chelators for thalassaemia. British journal of haematology, 1998, Volume: 101, Issue:3 Topics: Administration, Oral; Aza Compounds; Chelating Agents; Deferiprone; Deferoxamine; Edetic Acid; Human	1998
The controversial role of deferiprone in the treatment of thalassemia. The Journal of laboratory and clinical medicine, 2001, Volume: 137, Issue:5 Topics: Agranulocytosis; Arthralgia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Comb	2001
Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia. Annals of the New York Academy of Sciences, 1990, Volume: 612 Topics: Chelating Agents; Deferiprone; Drug Design; Humans; Iron; Iron Chelating Agents; Pyridines; Pyridone	1990
[Iron-chelating treatment]. Haematologica, 1989, Volume: 74, Issue:5 Suppl Topics: Chelation Therapy; Deferiprone; Deferoxamine; Erythropoiesis; Hemosiderosis; Humans; Iron; Iron Chel	1989

Article	Year
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood advances, 2022, 02-22, Volume: 6, Issue:4 Topics: Adolescent; Anemia, Sickle Cell; Blood Transfusion; Deferiprone; Deferoxamine; Female; Humans; Iron	2022
Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial. American journal of hematology, 2018, Volume: 93, Issue:2 Topics: Blood Transfusion; Chelation Therapy; Deferiprone; Female; Ferritins; Humans; Infant; Iron Chelating	2018
Deferiprone increases endothelial nitric oxide synthase phosphorylation and nitric oxide production. Canadian journal of physiology and pharmacology, 2018, Volume: 96, Issue:9 Topics: Adult; Blood Pressure; Deferiprone; Endothelial Cells; Female; Humans; Male; Nitric Oxide; Nitric Ox	2018
Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:1 Topics: Adult; Blood Transfusion; Deferasirox; Deferiprone; Drug Therapy, Combination; Female; Follow-Up Stu	2019
Long-term sequential deferiprone and deferasirox therapy in transfusion-dependent thalassaemia patients: a prospective clinical trial. British journal of haematology, 2019, Volume: 186, Issue:6 Topics: Adult; Blood Transfusion; Deferasirox; Deferiprone; Female; Follow-Up Studies; Humans; Male; Prospec	2019
Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. British journal of haematology, 2009, Volume: 145, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Femal	2009
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. European journal of haematology, 2010, Volume: 85, Issue:5 Topics: Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Ferritins; Humans; Iron; Iron C	2010
Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. Journal of bone and mineral metabolism, 2004, Volume: 22, Issue:1 Topics: Adolescent; Alkaline Phosphatase; Amino Acids; Body Weights and Measures; Bone and Bones; Bone Densi	2004
Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian pediatrics, 2004, Volume: 41, Issue:1 Topics: Blood Transfusion; Child; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; I	2004
Deferiprone, efficacy and safety. Indian journal of pediatrics, 2004, Volume: 71, Issue:3 Topics: Adolescent; Child; Child, Preschool; Deferiprone; Female; Humans; Iron Chelating Agents; Male; Pyrid	2004
Five-year trial of deferiprone chelation therapy in thalassaemia major patients. Acta haematologica, 2004, Volume: 112, Issue:4 Topics: Adolescent; Adult; Antibodies, Viral; Clinical Enzyme Tests; Deferiprone; Female; Ferritins; Heart F	2004
Safety of oral iron chelator deferiprone in young thalassaemics. European journal of haematology, 2005, Volume: 74, Issue:3 Topics: Blood Cell Count; Child; Child, Preschool; Deferiprone; Female; Follow-Up Studies; Humans; Iron Chel	2005
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica, 2006, Volume: 91, Issue:9 Topics: Adolescent; Adult; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Overlo	2006
Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Annals of hematology, 2008, Volume: 87, Issue:7 Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Deferiprone; Deferoxamine; Drug Admin	2008
Deferiprone-associated myelotoxicity. European journal of haematology, 1994, Volume: 53, Issue:5 Topics: Adult; Agranulocytosis; Deferiprone; Female; Hematopoiesis; Humans; Iron Chelating Agents; Male; Mid	1994
The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. International journal of clinical pharmacology and therapeutics, 1996, Volume: 34, Issue:7 Topics: Adolescent; Adult; Area Under Curve; Deferiprone; Erythrocyte Transfusion; Half-Life; Hemoglobins; H	1996
Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. Haematologica, 1998, Volume: 83, Issue:6 Topics: Adolescent; Adult; Biopsy; Deferiprone; Female; Humans; Iron Chelating Agents; Liver; Male; Pyridone	1998
Combined therapy with deferiprone and desferrioxamine. British journal of haematology, 1998, Volume: 103, Issue:2 Topics: Adolescent; Adult; Aged; beta-Thalassemia; Deferiprone; Deferoxamine; Dose-Response Relationship, Dr	1998
Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta haematologica, 1999, Volume: 101, Issue:4 Topics: Adolescent; Adult; Arthralgia; Child; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studie	1999
Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica, 2000, Volume: 85, Issue:2 Topics: Administration, Oral; Deferiprone; Humans; Iron Chelating Agents; Pyridones; Thalassemia; Treatment	2000
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood, 1992, Aug-01, Volume: 80, Issue:3 Topics: Adult; Deferiprone; Deferoxamine; Female; Ferritins; Follow-Up Studies; Humans; Iron; Iron Chelating	1992
Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload. The Journal of the Association of Physicians of India, 1991, Volume: 39, Issue:9 Topics: Adolescent; Chelation Therapy; Deferiprone; Hemochromatosis; Humans; Iron Chelating Agents; Pyridone	1991
Oral iron chelation with L1. Lancet (London, England), 1990, Mar-10, Volume: 335, Issue:8689 Topics: Administration, Oral; Adolescent; Adult; Chelation Therapy; Child; Clinical Trials as Topic; Deferip	1990
Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet (London, England), 1990, Nov-24, Volume: 336, Issue:8726 Topics: Adolescent; Adult; Anemia, Aplastic; Animals; Blood Transfusion; Child; Cohort Studies; Combined Mod	1990
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. British journal of haematology, 1990, Volume: 76, Issue:2 Topics: Anemia; Blood Transfusion; Deferiprone; Ferritins; Half-Life; Humans; Iron; Iron Chelating Agents; M	1990
Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations. British journal of haematology, 1990, Volume: 76, Issue:2 Topics: Adolescent; Adult; Aged; Anemia; Blood Transfusion; Deferiprone; Female; Humans; Iron; Iron Chelatin	1990
Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. Seminars in hematology, 1990, Volume: 27, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Drug A	1990
Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients. Annals of the New York Academy of Sciences, 1990, Volume: 612 Topics: Administration, Oral; Adult; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridon	1990
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. British medical journal (Clinical research ed.), 1987, Dec-12, Volume: 295, Issue:6612 Topics: Administration, Oral; Adolescent; Adult; Aged; Ascorbic Acid; Clinical Trials as Topic; Deferiprone;	1987

Article	Year
Deferiprone has less benefits on gut microbiota and metabolites in high iron-diet induced iron overload thalassemic mice than in iron overload wild-type mice: A preclinical study. Life sciences, 2022, Oct-15, Volume: 307 Topics: Animals; Cytokines; Deferiprone; Diet; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Iron; I	2022
Combined iron chelator with N-acetylcysteine exerts the greatest effect on improving cardiac calcium homeostasis in iron-overloaded thalassemic mice. Toxicology, 2019, 11-01, Volume: 427 Topics: Acetylcysteine; Animals; Calcium; Deferiprone; Heart; Homeostasis; Iron Chelating Agents; Iron Overl	2019
Deferiprone and efonidipine mitigated iron-overload induced neurotoxicity in wild-type and thalassemic mice. Life sciences, 2019, Dec-15, Volume: 239 Topics: Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Deferiprone; Dihydropyridines; Disease	2019
Institutional conflict of interest: attempting to crack the deferiprone mystery. Journal of medical ethics, 2021, Volume: 47, Issue:8 Topics: Conflict of Interest; Deferiprone; Humans; Informed Consent; Pyridones; Retrospective Studies; Thala	2021
Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study. Indian journal of pediatrics, 2021, Volume: 88, Issue:4 Topics: Benzoates; beta-Thalassemia; Child; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Ov	2021
Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. Annals of hematology, 2020, Volume: 99, Issue:10 Topics: Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine; Drug Evaluati	2020
Dual Oral Iron Chelation in Thalassemia: Need for Robust Evidence. Indian journal of pediatrics, 2021, Volume: 88, Issue:4 Topics: Child; Deferasirox; Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Prospective Studies;	2021
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran. Hemoglobin, 2021, Volume: 45, Issue:2 Topics: Adult; Benzoates; beta-Thalassemia; Cross-Sectional Studies; Deferasirox; Deferiprone; Deferoxamine;	2021
Thalassemia: Yesterday, Today, Tomorrow. American journal of hematology, 2017, Volume: 92, Issue:6 Topics: Attitude of Health Personnel; Attitude to Health; Chelation Therapy; Cyprus; Deferiprone; Deferoxami	2017
Premature ventricular contractions as a side effect of filgrastim in a child with B-thalassaemia. Cardiology in the young, 2018, Volume: 28, Issue:1 Topics: Agranulocytosis; Child; Deferiprone; Electrocardiography, Ambulatory; Filgrastim; Humans; Male; Pyri	2018
Chelation protocols for the elimination and prevention of iron overload in thalassaemia. Frontiers in bioscience (Landmark edition), 2018, 01-01, Volume: 23, Issue:6 Topics: Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hum	2018
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience. La Radiologia medica, 2018, Volume: 123, Issue:8 Topics: Adolescent; Adult; Benzoates; Blood Component Transfusion; Chelation Therapy; Child; Deferasirox; De	2018
Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients. American journal of hematology, 2018, Volume: 93, Issue:10 Topics: Adolescent; Adult; Blood Transfusion; Chelation Therapy; Deferasirox; Deferiprone; Drug Administrati	2018
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert opinion on drug safety, 2013, Volume: 12, Issue:5 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Mar	2013
Distal ulnar changes in children with thalassemia and deferiprone related arthropathy. Pediatric blood & cancer, 2013, Volume: 60, Issue:12 Topics: Child; Child, Preschool; Deferiprone; Female; Humans; Infant; Iron Chelating Agents; Knee Joint; Mal	2013
Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents. Hemoglobin, 2014, Volume: 38, Issue:5 Topics: Adolescent; Adult; Benzoates; Chelation Therapy; Child; Child, Preschool; Deferasirox; Deferiprone;	2014
Tandem measurements of iron and creatinine by cross injection analysis with application to urine from thalassemic patients. Talanta, 2015, Volume: 133 Topics: Azo Compounds; Colorimetry; Creatinine; Deferiprone; Equipment Design; Ferric Compounds; Flow Inject	2015
Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia. Current drug safety, 2016, Volume: 11, Issue:2 Topics: Administration, Oral; Adolescent; Adverse Drug Reaction Reporting Systems; Agranulocytosis; Blood Tr	2016
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Experimental physiology, 2016, Volume: 101, Issue:4 Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Ca	2016
The Italian multiregional thalassemia registry: Centers characteristics, services, and patients' population. Hematology (Amsterdam, Netherlands), 2016, Volume: 21, Issue:7 Topics: Adult; Ambulatory Care Facilities; Blood Transfusion; Chelation Therapy; Deferiprone; Deferoxamine;	2016
Frequency of neutropenia among Turkish and Syrian pediatric thalassemia patients under deferiprone monotherapy. Pediatric hematology and oncology, 2016, Volume: 33, Issue:1 Topics: Adolescent; Anemia, Aplastic; Anemia, Hemolytic; Blood Transfusion; Bone Marrow Diseases; Bone Marro	2016
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia. Indian pediatrics, 2016, Volume: 53, Issue:3 Topics: Adolescent; Benzoates; Child; Child, Preschool; Deferasirox; Deferiprone; Drug Therapy, Combination;	2016
Neurological Involvement in a Thalassemic Child Receiving Deferiprone. Journal of pediatric hematology/oncology, 2016, Volume: 38, Issue:5 Topics: Child; Deferiprone; Female; Humans; Iron Chelating Agents; Nervous System Diseases; Pyridones; Thala	2016
Deferiprone-induced agranulocytosis: 20 years of clinical observations. American journal of hematology, 2016, Volume: 91, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Child; Child, Preschool; Clinical Trial	2016
Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice. European journal of pharmacology, 2017, Mar-15, Volume: 799 Topics: Aminophylline; Animals; Apoptosis; Atropine; Blood Pressure; Calcium Channel Blockers; Calcium Chann	2017
Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier. International journal of hematology, 2009, Volume: 89, Issue:2 Topics: Adult; Blood Transfusion; Deferiprone; Deferoxamine; Hepatitis B; Hepatitis B virus; Humans; Iron Ch	2009
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Chelation Therapy; Chronic Disease; Cyprus; Deferiprone; Deferoxamine; Female; Ferritins; Genetic Te	2009
Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxa Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Adolescent; Adult; Chelation Therapy; Child; Deferiprone; Deferoxamine; Diagnosis, Differential; Dru	2009
A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Blood Transfusion; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, C	2009
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Aeromonas hydrophila; Benzoates; Blood Transfusion; Deferasirox; Deferiprone; Deferoxamine; Gram-Neg	2009
Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin, 2009, Volume: 33, Issue:5 Topics: Animals; Antioxidants; Benzoates; Chelation Therapy; Copper; Deferasirox; Deferiprone; Deferoxamine;	2009
Combining two orally active iron chelators for thalassemia. Annals of hematology, 2010, Volume: 89, Issue:11 Topics: Administration, Oral; Adolescent; Adult; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; P	2010
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Translational research : the journal of laboratory and clinical medicine, 2010, Volume: 156, Issue:2 Topics: Adult; Chromatography, High Pressure Liquid; Deferiprone; Deferoxamine; Female; Ferric Compounds; Hu	2010
Pathogenesis and management of iron toxicity in thalassemia. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Homeostasis; Humans; Iron; Iron Chelating Agents;	2010
Deferiprone. Annals of the New York Academy of Sciences, 2010, Volume: 1202 Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Liver; Pyridones; Randomized Control	2010
Iron chelation in thalassemia: time to reconsider our comfort zones. Expert review of hematology, 2011, Volume: 4, Issue:1 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Ferritins; Humans; Iro	2011
Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia. Journal of paediatrics and child health, 2011, Volume: 47, Issue:11 Topics: Adolescent; Adult; Blood Transfusion; Child; Child, Preschool; Cohort Studies; Deferiprone; Female;	2011
FDA panel recommends approval of deferiprone. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2011, Nov-08, Volume: 183, Issue:16 Topics: Agranulocytosis; Deferiprone; Drug Approval; Drug Labeling; Humans; Iron Chelating Agents; Off-Label	2011
Deferiprone approved for iron overload. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011, Nov-15, Volume: 68, Issue:22 Topics: Deferiprone; Drug Approval; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thal	2011
Health-related quality of life in Thai thalassemic children treated with iron chelation. The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:4 Topics: Adolescent; Age Factors; Benzoates; Child; Child, Preschool; Cross-Sectional Studies; Deferasirox; D	2011
The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies. Toxicology mechanisms and methods, 2013, Volume: 23, Issue:1 Topics: Chelating Agents; Chelation Therapy; Deferiprone; Deferoxamine; Edetic Acid; Humans; Iron Overload;	2013
A postmodern moral tale: the ethics of research relationships. Nature reviews. Drug discovery, 2002, Volume: 1, Issue:4 Topics: Deferiprone; Ethics, Medical; Humans; Iron Chelating Agents; Morals; Pyridones; Thalassemia	2002
Treatment of thalassoemia--the current scenario. Journal of the Indian Medical Association, 2002, Volume: 100, Issue:2 Topics: Azacitidine; Bone Marrow Transplantation; Deferiprone; Fetal Hemoglobin; Genetic Therapy; Humans; Hy	2002
The Olivieri case. The New England journal of medicine, 2003, Feb-27, Volume: 348, Issue:9 Topics: Deferiprone; Drug Approval; Interinstitutional Relations; Iron Chelating Agents; Iron Overload; Pyri	2003
Patients' health or company profits? The commercialisation of academic research. Science and engineering ethics, 2003, Volume: 9, Issue:1 Topics: Biomedical Research; Child; Clinical Trials as Topic; Commodification; Conflict of Interest; Deferip	2003
The Olivieri Report--a compelling study of the growing tensions in clinical research. Science and engineering ethics, 2003, Volume: 9, Issue:1 Topics: Clinical Trials as Topic; Conflict of Interest; Deferiprone; Disclosure; Drug Evaluation; Drug Indus	2003
Experience with the oral iron chelator deferiprone in transfusion-dependent children. The Ceylon medical journal, 2002, Volume: 47, Issue:4 Topics: Administration, Oral; Adolescent; Anemia; Blood Transfusion; Child; Child, Preschool; Deferiprone; F	2002
Do we need more iron-chelating drugs? Lancet (London, England), 2003, Aug-09, Volume: 362, Issue:9382 Topics: Benzoates; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron Overload; Pyr	2003
Whistleblower vows to fight on. BMJ (Clinical research ed.), 2004, Jan-24, Volume: 328, Issue:7433 Topics: Confidentiality; Deferiprone; Drug Approval; Drug Industry; European Union; Humans; Iron Chelating A	2004
Industry and the academy: conflicts of interest in contemporary health research. Health law journal, 2002, Volume: 10 Topics: Biomedical Research; Clinical Trials as Topic; Conflict of Interest; Deferiprone; Drug Industry; Hos	2002
Independent clinical trials. Lancet (London, England), 2004, Mar-27, Volume: 363, Issue:9414 Topics: Anemia, Sickle Cell; Deferiprone; Deferoxamine; Drug Industry; Financial Support; Humans; Multicente	2004
CJEC 2004/2, case T-326/99, Olivieri/Commisssion. European journal of health law, 2004, Volume: 11, Issue:1 Topics: Deferiprone; Humans; Iron Chelating Agents; Legislation, Drug; Marketing; Pyridones; Thalassemia	2004
Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia. British journal of haematology, 2004, Volume: 127, Issue:3 Topics: Cardiomyopathies; Deferiprone; Humans; Iron Chelating Agents; Magnetic Resonance Imaging; Myocardium	2004
Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs. Haematologica, 2006, Volume: 91, Issue:6 Suppl Topics: Deferiprone; Deferoxamine; Drug Therapy, Combination; Humans; Iron Chelating Agents; Iron Overload;	2006
Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Adolescent; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Chelatio	2006
Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2. Hemoglobin, 2006, Volume: 30, Issue:2* Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Cardiomyopathies; Chelation Therapy; Combined Mod	2006
Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey. Hemoglobin, 2006, Volume: 30, Issue:2 Topics: Abortion, Eugenic; Adolescent; Adult; Blood Transfusion; Chelation Therapy; Combined Modality Therap	2006
Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica, 2006, Volume: 91, Issue:9 Topics: Cyprus; Deferiprone; Deferoxamine; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents;	2006
Physical growth patterns and dental caries in thalassemia. Indian pediatrics, 2006, Volume: 43, Issue:12 Topics: Adolescent; Adult; Child; Child, Preschool; Deferiprone; Deferoxamine; Dental Caries; Female; Ferrit	2006
Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood, 2007, Jun-15, Volume: 109, Issue:12 Topics: Agranulocytosis; Anemia, Diamond-Blackfan; Blood Cell Count; Bone Marrow; Child; Contraindications;	2007
Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma. Medicinal chemistry (Shariqah (United Arab Emirates)), 2007, Volume: 3, Issue:5 Topics: Chromatography, High Pressure Liquid; Curcumin; Deferiprone; Deferoxamine; Humans; Iron; Iron Chelat	2007
Transfusion-dependent thalassaemia: a new era. The Medical journal of Australia, 2008, Jan-21, Volume: 188, Issue:2 Topics: Benzoates; Cardiomyopathies; Deferasirox; Deferiprone; Deferoxamine; Drug Prescriptions; Erythrocyte	2008
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic. The Medical journal of Australia, 2008, Jan-21, Volume: 188, Issue:2 Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug	2008
Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Cardiomyopathies; Chelation Therapy; Deferiprone; Deferoxamine; Female; Ferritins; Humans; Iron; Iro	2008
Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin, 2008, Volume: 32, Issue:1-2 Topics: Adult; Chelation Therapy; Clinical Protocols; Deferiprone; Deferoxamine; Drug Therapy, Combination;	2008
Deferiprone in iron overload. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Antibodies, Antinuclear; Autoantibodies; Chemistry, Pharmaceutical; Deferiprone; Histones; Humans; I	1995
Deferiprone in iron overload. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Deferiprone; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Joint Diseases; Neutropenia;	1995
Compliance with iron-chelation treatment after bone marrow transplantation. Lancet (London, England), 1994, Mar-05, Volume: 343, Issue:8897 Topics: Bone Marrow Transplantation; Chelation Therapy; Deferiprone; Humans; Iron; Iron Chelating Agents; Pa	1994
Arthropathy in thalassaemia patients receiving deferiprone. Lancet (London, England), 1994, Jul-23, Volume: 344, Issue:8917 Topics: Deferiprone; Humans; Iron Chelating Agents; Joint Diseases; Pyridones; Thalassemia	1994
Toxicity of oral iron chelator L1. The Journal of the Association of Physicians of India, 1993, Volume: 41, Issue:6 Topics: Adolescent; Adult; Blood Transfusion; Child; Clinical Trials as Topic; Deferiprone; Developing Count	1993
Autoantibodies in thalassaemia major: relationship with oral iron chelator L1. The Journal of the Association of Physicians of India, 1993, Volume: 41, Issue:6 Topics: Adolescent; Adult; Antibodies, Antinuclear; Autoimmune Diseases; Blood Transfusion; Child; Deferipro	1993
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. Journal of clinical pathology, 1994, Volume: 47, Issue:7 Topics: Adolescent; Adult; Blood Glucose; Deferiprone; Deferoxamine; Diabetes Mellitus; Female; Glucose Tole	1994
Development of oral iron chelator L1. Lancet (London, England), 1993, Apr-24, Volume: 341, Issue:8852 Topics: Agranulocytosis; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Pyridones; Thalassemia	1993
Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. European journal of haematology, 1994, Volume: 52, Issue:3 Topics: Bone Marrow Cells; Cell Division; Deferiprone; Deferoxamine; Hematopoiesis; Humans; In Vitro Techniq	1994
Comparison of the pharmacokinetics of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients. International journal of clinical pharmacology, therapy, and toxicology, 1993, Volume: 31, Issue:12 Topics: Adolescent; Adult; Child; Deferiprone; Ferrous Compounds; Humans; Iron Chelating Agents; Male; Pyrid	1993
An oral treatment for iron overload in thalassemia? Hepatology (Baltimore, Md.), 1996, Volume: 23, Issue:2 Topics: Administration, Oral; Chelation Therapy; Deferiprone; Hemosiderosis; Humans; Iron Chelating Agents;	1996
The effectiveness of deferiprone in thalassemia. Blood, 1997, Jul-15, Volume: 90, Issue:2 Topics: Deferiprone; Deferoxamine; Humans; Iron; Iron Chelating Agents; Pyridones; Thalassemia	1997
Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. The Journal of clinical investigation, 1997, Sep-15, Volume: 100, Issue:6 Topics: Animals; Cell Survival; Deferiprone; Erythrocyte Membrane; Globins; Iron; Iron Chelating Agents; Mic	1997
HSC clinical trials controversy continues. Hospital for Sick Children. Nature medicine, 1999, Volume: 5, Issue:1 Topics: Biomedical Research; Child; Clinical Trials as Topic; Contracts; Deferiprone; Disclosure; Hospitals,	1999
Controversial HSC clinical trials report made public. Hospital for Sick Children. Nature medicine, 1999, Volume: 5, Issue:1 Topics: Biomedical Research; Child; Clinical Trials as Topic; Contracts; Deferiprone; Disclosure; Drug Indus	1999
Independent review adds to controversy at Sick Kids. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1999, Feb-09, Volume: 160, Issue:3 Topics: Advisory Committees; Biomedical Research; Child; Child Welfare; Clinical Trials as Topic; Conflict o	1999
Academia and industry: lessons from the unfortunate events in Toronto. Lancet (London, England), 1999, Mar-06, Volume: 353, Issue:9155 Topics: Academic Medical Centers; Clinical Trials as Topic; Deferiprone; Drug Industry; Humans; Iron Chelati	1999
Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells. British journal of haematology, 1999, Volume: 105, Issue:4 Topics: Adult; Anemia, Sickle Cell; Biological Transport; Deferiprone; Erythrocytes; Humans; Iron Chelating	1999
Deferiprone for thalassaemia. Lancet (London, England), 2000, Jul-29, Volume: 356, Issue:9227 Topics: Deferiprone; Humans; Iron Chelating Agents; Iron Overload; Pyridones; Thalassemia	2000
Deferiprone for thalassaemia. Lancet (London, England), 2000, Oct-21, Volume: 356, Issue:9239 Topics: Administration, Oral; Deferiprone; Humans; Iron Chelating Agents; Pyridones; Thalassemia	2000
Deferiprone or fatal iron toxic effects? Lancet (London, England), 2001, Mar-17, Volume: 357, Issue:9259 Topics: Deferiprone; Humans; Iron Chelating Agents; Liver Cirrhosis; Pyridones; Thalassemia	2001
Olivieri to testify against Apotex in Europe. Nature medicine, 2001, Volume: 7, Issue:6 Topics: Canada; Deferiprone; Drug Industry; Europe; Faculty; History, 21st Century; Humans; Iron Chelating A	2001
Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. Journal of chromatography. B, Biomedical sciences and applications, 2001, May-05, Volume: 755, Issue:1-2 Topics: Benzoates; Calibration; Chromatography, High Pressure Liquid; Deferasirox; Deferiprone; Deferoxamine	2001
Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients. Haematologia, 2002, Volume: 31, Issue:4 Topics: Adolescent; Adult; Child; Deferiprone; Female; Humans; Interpersonal Relations; Interview, Psycholog	2002
Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood, 1992, May-15, Volume: 79, Issue:10 Topics: Adult; Deferiprone; Ferritins; Follow-Up Studies; Humans; Iron; Iron Chelating Agents; Liver; Magnet	1992
Fatal systemic lupus erythematosus in patient taking oral iron chelator L1. Lancet (London, England), 1991, Feb-02, Volume: 337, Issue:8736 Topics: Adolescent; Antibodies, Antinuclear; Child; Deferiprone; Female; Humans; Lupus Erythematosus, System	1991
Compliance assessed by the Medication Event Monitoring System. Archives of disease in childhood, 1991, Volume: 66, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Child; Deferiprone; Drug Packaging; Female; Humans; Iron Ch	1991
Iron chelation. The Journal of the Association of Physicians of India, 1991, Volume: 39, Issue:9 Topics: Chelation Therapy; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron; Iron Chelating Agents;	1991
Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clinical pharmacology and therapeutics, 1991, Volume: 50, Issue:3 Topics: Adolescent; Adult; Child; Deferiprone; Female; Half-Life; Humans; Iron; Iron Chelating Agents; Male;	1991
A high-performance liquid chromatographic method for the measurement of the iron chelator 1,2-dimethyl-3-hydroxypyridin-4-one in human plasma. Therapeutic drug monitoring, 1991, Volume: 13, Issue:1 Topics: Adolescent; Child; Chromatography, High Pressure Liquid; Deferiprone; Humans; Iron Chelating Agents;	1991
L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. British journal of haematology, 1990, Volume: 76, Issue:4 Topics: Adolescent; Adult; Child; Deferiprone; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Male;	1990
Development of an HPLC method for measuring orally administered 1-substituted 2-alkyl-3-hydroxypyrid-4-one iron chelators in biological fluids. Clinical chemistry, 1990, Volume: 36, Issue:1 Topics: Adolescent; Blood Transfusion; Body Fluids; Chromatography, High Pressure Liquid; Deferiprone; Human	1990
Safety of oral iron chelator L1. Lancet (London, England), 1989, Aug-19, Volume: 2, Issue:8660 Topics: Administration, Oral; Animals; Deferiprone; Drug Evaluation; Humans; Iron Chelating Agents; Male; Py	1989
Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines. Progress in clinical and biological research, 1989, Volume: 309 Topics: Adult; Aged; Blood Transfusion; Deferiprone; Humans; Iron; Iron Chelating Agents; Middle Aged; Neura	1989

deferiprone and Thalassemias